Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes (CROSBI ID 201602)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Mehta, S.R. ; Yusuf, S. ; ... ; Polić, Stojan ; ... ; Wu, W.C. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes // The New England journal of medicine, 363 (2010), 10; 930-942. doi: 10.1056/NEJMoa0909475

Podaci o odgovornosti

Mehta, S.R. ; Yusuf, S. ; ... ; Polić, Stojan ; ... ; Wu, W.C.

engleski

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have not been established for either agent. We randomly assigned, in a 2-by-2 factorial design, 25, 086 patients with an acute coronary syndrome who were referred for an invasive strategy to either double-dose clopidogrel (a 600-mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter) or standard-dose clopidogrel (a 300-mg loading dose and 75 mg daily thereafter) and either higher-dose aspirin (300 to 325 mg daily) or lower-dose aspirin (75 to 100 mg daily). The primary outcome was cardiovascular death, myocardial infarction, or stroke at 30 days. The primary outcome occurred in 4.2% of patients assigned to double-dose clopidogrel as compared with 4.4% assigned to standard-dose clopidogrel (hazard ratio, 0.94 ; 95% confidence interval [CI], 0.83 to 1.06 ; P=0.30). Major bleeding occurred in 2.5% of patients in the double-dose group and in 2.0% in the standard-dose group (hazard ratio, 1.24 ; 95% CI, 1.05 to 1.46 ; P=0.01). Double-dose clopidogrel was associated with a significant reduction in the secondary outcome of stent thrombosis among the 17, 263 patients who underwent PCI (1.6% vs. 2.3% ; hazard ratio, 0.68 ; 95% CI, 0.55 to 0.85 ; P=0.001). There was no significant difference between higher-dose and lower-dose aspirin with respect to the primary outcome (4.2% vs. 4.4% ; hazard ratio, 0.97 ; 95% CI, 0.86 to 1.09 ; P=0.61) or major bleeding (2.3% vs. 2.3% ; hazard ratio, 0.99 ; 95% CI, 0.84 to 1.17 ; P=0.90). In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke.

Clopidogrel; aspirin; acute coronary syndromes

CURRENT-OASIS 7 Investigators.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

363 (10)

2010.

930-942

objavljeno

0028-4793

10.1056/NEJMoa0909475

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost